In the last trading session, 4.48 million Enlivex Therapeutics Ltd (NASDAQ:ENLV) shares changed hands as the company’s beta touched 1.02. With the company’s per share price at $1.30 changed hands at $0.22 or 20.37% during last session, the market valuation stood at $27.83M. ENLV’s last price was a discount, traded about -253.08% off its 52-week high of $4.59. The share price had its 52-week low at $0.81, which suggests the last value was 37.69% up since then. When we look at Enlivex Therapeutics Ltd’s average trading volume, we note the 10-day average is 0.22 million shares, with the 3-month average coming to 155.14K.
Analysts gave the Enlivex Therapeutics Ltd (ENLV) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ENLV as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Enlivex Therapeutics Ltd’s EPS for the current quarter is expected to be -0.16.
Enlivex Therapeutics Ltd (NASDAQ:ENLV) trade information
Instantly ENLV was in green as seen at the end of in last trading. With action 21.50%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -51.85%, with the 5-day performance at 21.50% in the green. However, in the 30-day time frame, Enlivex Therapeutics Ltd (NASDAQ:ENLV) is -4.41% down. Looking at the short shares, we see there were 99233.0 shares sold at short interest cover period of 0.56 days.
The consensus price target for the stock as assigned by Wall Street analysts is 15, meaning bulls need an upside of 91.33% from its current market value. According to analyst projections, ENLV’s forecast low is 15 with 15 as the target high. To hit the forecast high, the stock’s price needs a -1053.85% plunge from its current level, while the stock would need to soar -1053.85% for it to hit the projected low.
Enlivex Therapeutics Ltd (ENLV) estimates and forecasts
Data shows that the Enlivex Therapeutics Ltd share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -3.70% over the past 6 months, a 55.13% in annual growth rate that is considerably higher than the industry average of 16.60%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 32.51%. The 2024 estimates are for Enlivex Therapeutics Ltd earnings to increase by 56.73%.
ENLV Dividends
Enlivex Therapeutics Ltd is expected to release its next quarterly earnings report in January.
MORGAN STANLEY holds the second largest percentage of outstanding shares, with 1.3077% or 0.24 million shares worth $0.35 million as of 2024-06-30.
